Skip to main content
. 2023 Jan 13;27(2):52. doi: 10.3892/mmr.2023.12939

Figure 1.

Figure 1.

Effect of bicalutamide, enzalutamide and apalutamide on the expression of STEAP1 and KLK3 in LNCaP-WT and LNCaP-STEAP1 knockdown prostate cancer cells. STEAP1 and KLK3 expression levels in LNCaP cells following transfection with siRNA for 24 h following treatment with 100 µM of BIC, or 10 µM of ENZA or 10 µM of APA for 24 h. Relative (A) STEAP1 mRNA, (B) STEAP1 protein and (C) KLK3 mRNA expression were determined by reverse transcription-quantitative PCR following normalization with the β2M housekeeping gene and western blot after normalization with total protein as represented in (D). Representative immunoblots are also showed in (D). Results are expressed as fold-variation relative to LNCaP-WT (control group). Error bars indicate mean ± standard error of the mean (n≥3). **P<0.01 and ****P<0.0001 vs. the LNCaP-WT condition; $$P<0.01, $$$P<0.001 and $$$$P<0.0001 vs. LNCaP-WT plus respective drug. STEAP1, six transmembrane epithelial antigen of the prostate 1; KLK3, kallikrein related peptidase 3; WT, wild type; siRNA, small interfering RNA; BIC, bicalutamide; ENZA, enzalutamide; APA, apalutamide; β2M, β-2-microglobulin.